The little yellow duck that attracts wealth: the strategic "golden pit" for value investors in innovative drugs
When the market falls into irrational killings, rational pricing will be temporarily absent.
Back on October 9, 2025, InnoCare Pharmaceutical Co., Ltd. reached a blockbuster BD deal of over US$2 billion with Zenas, setting a record for self-immune small molecule drugs going overseas. However, the capital market's response was surprising - both A-shares and Hong Kong stocks fell. This scene is an intuitive reflection of InnoCare Pharmaceutical Co., Ltd. being underestimated by the market.
When the company just announced its 2025 results, with revenue of 2.37 billion yuan and net profit turning a profit for the first time to 640 million yuan, the Hong Kong stock market value was currently around HK$22 billion, less than half of the A-share market value. Among the many pure innovative drug stocks with book-to-book ratios in the Hong Kong stock market exceeding 6 or even 10, InnoCare Pharmaceutical Co., Ltd., whose price-to-book ratio has remained around 3 for a long time, appears to be quite undervalued.
This is not a rational valuation discount, nor is it a true discovery of value, but an underestimation of intrinsic value.
The triple engine roars, and value reconstruction is imminent
Engine 1: The profit turning point is established, from "expectation" to "realization"
The 2025 results announced a historic turning point for InnoCare Pharmaceutical Co., Ltd.: revenue of 2.37 billion yuan (+135%) and net profit of 640 million yuan, turning losses into profits for the first time. This means that the company has completely bid farewell to the "money-burning R&D" stage and entered a positive cycle of "self-production".
Looking deeper, this profit does not rely on compressed R&D - R&D investment will increase by 16.9% in 2025, reaching 950 million yuan, laying the foundation for the company's sustainable development. The company's gross profit margin exceeds 90%, and the company's cash flow has increased slightly compared to the end of 2024. This three-high model of "high growth, high gross profit, and high R&D" is the ideal form for innovative pharmaceutical companies.
Whether it is bravely facing the capital winter or recovering, sufficient cash flow and good hematopoietic function are the greatest confidence that InnoCare Pharmaceutical Co., Ltd. can continue, efficiently and smoothly promote the clinical trials of core products and invest in new technology platforms, thereby building a strong ability to transform technological innovation into long-term sustainable growth, and forming a virtuous cycle for the company's development.
Engine 2: Commercial fission, from "burning money" to "printing money"
InnoCare Pharmaceutical Co., Ltd. is undergoing the most precious transformation for innovative pharmaceutical companies - the death valley crossing from clinical to commercialization.
The core product Orelabrutinib (Inokat®) has rapidly increased in volume, and its growth rate has always exceeded the sales guidance issued by the company. More importantly, as the only BTK inhibitor approved in China for the treatment of marginal zone lymphoma (MZL), orelabrutinib has exclusive medical insurance status. At the same time, orelabrutinib is about to be applied for listing for the treatment of ITP, which means that orelabrutinib will soon enter the autoimmune field from hematological tumors, and future sales are more promising.
In April 2025, Orelabrutinib was approved as a new indication for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). As the indication advances from second-line to first-line and is included in the guideline level 1 recommendation, Orelabrutinib will benefit more patients.
The approval of tanxituzumab (Mennocet®) will inject momentum into the performance in 2026 - it is the first CD19 monoclonal antibody approved in China for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). As the first domestically produced pan-TRK inhibitor approved for the treatment of NTRK fusion-positive solid tumors, zolecitinib (Inoxin®) is not limited to tumor types and provides treatment options for more NTRK fusion-positive patients with different tumor types. The second-generation pan-TRK inhibitor can overcome the acquired resistance of the first-generation TRK inhibitors.
In addition, many of InnoCare Pharmaceutical Co., Ltd.'s pipelines have entered late clinical stages, and pipelines such as BCL2 inhibitor Mesutoclax (ICP-248), TYK2 inhibitor Soficitinib (ICP-332), and ICP-488 have all entered Phase III clinical trials. Vitiligo, atopic dermatitis, psoriasis and other indications in the field of autoimmunity have formed a matrix. The success of any of these pipelines is expected to replicate the commercialization miracle of orelabrutinib.
Engine 3: BD is going global, from "local" to "global"
In the past year, InnoCare Pharmaceutical Co., Ltd. has delivered amazing results in its internationalization strategy.
In October 2025, a transaction of over US$2 billion was reached with Zenas, setting a new record for small molecule autoimmune transactions. This is not only an injection of capital, but also an endorsement of InnoCare Pharmaceutical Co., Ltd.’s R&D capabilities, marking a solid step forward in globalization. Currently, according to the annual report released by Zenas, the global phase III of multiple sclerosis (MS) is advancing as planned. In the current field of MS treatment, CD20 drugs dominate. Among them, orrelizumab is the only drug approved to treat PPMS in the world. Its sales in 2025 will reach US$9 billion, making it one of the top three autoimmune drugs in the world and among the top ten of all drugs in the world. This shows the vastness of the MS market.
In January 2025, it reached an over $500 million TCE dual-antibody licensing cooperation with Prolium, and clinical development in the field of treating severe autoimmune diseases has been launched. Recently, the progress of Connoia's newco has made the market full of expectations for this globalization path.
In addition, InnoCare Pharmaceutical Co., Ltd.'s numerous pipelines are full of globalization potential. In addition to BCL2 and TYK2, which are entering the later stage, there are also exciting pipelines. For example, the VAV1 target target is the first, Novartis spent 2.25 billion US dollars to introduce a phase 1 clinical stage molecular collagen degrader, and Huaibi's successor, InnoCare Pharmaceutical Co., Ltd., self-developed the world's second clinically approved ICP-538, which may also bring surprises. Of course there are ADC, dual resistance, etc.
Catalysts for revaluation: three trigger points
The current undervaluation of Hong Kong stocks precisely provides "asymmetric opportunities" for rational investors. Any of the following catalysts could trigger a valuation repair:
Catalyst 1: Industry beta and policy catalysis. The government work report at the two sessions in 2026 clearly listed biomedicine as an emerging pillar industry of the country. Innovative drugs are no longer a "cost item" under medical insurance fee control, but an "engine" for the country's economic transformation and upgrading. It is expected to bring about policy changes, such as easing the pressure on medical insurance negotiations and smoothing hospital admissions, etc., which will fundamentally improve the operating environment of innovative drug companies and lead to valuation reconstruction.
Catalyst 2: Advancement of overseas licensing. Orelabrutinib is the only BTK inhibitor in the world that is simultaneously deployed for the two major progressive MS indications of naSPMS and PPMS. With its high selectivity and excellent blood-brain barrier penetration, orelabrutinib is expected to break through the limitations of existing therapies and become a core product with BIC potential in the treatment of progressive multiple sclerosis, opening up global valuation space.
Catalyst 3: A series of pipeline data readouts. Phase III data of orelabrutinib in essential thrombocytopenia (ITP), phase III data of soficitinib (ICP-332) in the treatment of atopic dermatitis (AD), phase II data in the treatment of vitiligo, urticaria and psoriasis, and phase III data of ICP-488 in the treatment of psoriasis, etc. The phase III data of Mesutoclax (ICP-248) combined with orelabrutinib in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as the data readout of the company's first ADC innovative drug, are full of expectations and prove that the company has the platform ability to continue to produce blockbuster pipelines.
Conclusion: Look for valuation reversal opportunities in troughs
Investment guru John Templeton said: "The bull market is born in pessimism, grows in doubt, matures in optimism, and is destroyed in fanaticism." The current situation of the Hong Kong stock market of InnoCare Pharmaceutical Co., Ltd. is exactly in the growth zone of "to doubt".
What we see is this: a biotechnology company that has achieved profitability for the first time, its pipeline has entered the harvest period, and its BD capabilities have been internationally recognized, but its Hong Kong stock market value is only about HK$22 billion. InnoCare Pharmaceutical Co., Ltd.'s discount is not a margin of safety, but a cognitive time difference.
InnoCare Pharmaceutical Co., Ltd. has made its first profit and biopharmaceuticals have been included in the country's emerging pillar industries. The Hong Kong stock market of InnoCare Pharmaceutical Co., Ltd., this pearl in the "golden pit", is waiting for the opportunity to soar into the sky.